Li-Chuan Hsu

Dr. Li-Chuan Hsu

Kaohsiung Veterans General Hospital
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Li-Chuan HsuLi-Chuan Hsu
Li-Chuan Hsu
Kuan-Hao TsuiKuan-Hao Tsui
Kuan-Hao Tsui
CHENGCHUNG WEICHENGCHUNG WEI
CHENGCHUNG WEI
HYHei-Tung Yip
Hei-Tung Yip
YHYao-min HUNG
Yao-min HUNG
RCRenin Chang
Renin Chang
Objective. This study investigated whether women with a history of human papillomavirus (HPV) infection have an increased risk of infertility. Material and Methods. All patients with an HPV infection (n = 11,198) in Taiwan’s National Health Insurance Research Database (2000–2012) were propensity score matched with control subjects (n = 11,198) without an HPV infection by age, sex, index year, and relevant co-morbidities. Both groups were tracked until a diagnosis of infertility was recorded. The Chi-square test was used to analyze the distribution of demographic characteristics in the HPV group and non-HPV group. A Cox proportional hazards regression was used to estimate the hazard ratios (HRs) for the development of infertility, adjusting for age, sex, and co-morbidities. The Kaplan–Meier method was used to plot the cumulative incidence curves. We also performed negative controls to test for possible unmeasured confounding. Results. The HPV cohort had a higher risk of infertility. The adjusted HR (aHR) was found to be 1.39 (95% CI = 1.19–1.63) after adjusting for demographic characteristics and relevant co-morbidities. In the age subgroup analysis, patients with an HPV infection had an increased risk of infertility compared to the non-HPV cohort in the group aged 26 to 35 years (aHR, 1.53; 95% CI = 1.24–1.88). As we used propensity score matching to treat measurable confounders and negative controls to access unmeasured confounders, the findings of the study are robust. Conclusions. Among females of reproductive age, HPV infection is a potential risk factor that predisposes individuals to subsequent infertility.

Verified
Journal Article
Open access
PDF file
Li-Chuan HsuLi-Chuan Hsu
Li-Chuan Hsu
Chia-Jung LiChia-Jung Li
Chia-Jung Li
Li-Te LinLi-Te Lin
Li-Te Lin
LPLi-Fei Pan
Li-Fei Pan
ZWZhi-Hong Wen
Zhi-Hong Wen
Kuan-Hao TsuiKuan-Hao Tsui
Kuan-Hao Tsui
Secreted phosphoprotein 1 (SPP1), also known as osteopontin (OPN), is located on chromosome 4q22.1. This multifunctional secreted acidic glycoprotein is expressed intracellularly and extracellularly in various tissues, where it interacts with regulatory proteins and pro-inflammatory immune chemokines, contributing to the pathogenesis of multiple diseases. Nevertheless, the intricate genetic connections between SPP1 and ovarian aging remain largely unexplored. This study aims to bridge this knowledge gap by delving into ovarian aging and its associations with SPP1 using multi-omics data analysis. Our findings indicate that SPP1 is a potential gene related to ovarian aging. To comprehend the role of SPP1, we conducted spatial transcriptomic analyses on young and aged female mouse ovaries, revealing a significant decline in SPP1 expression in the aging group compared to the young group. Similarly, a significantly low level of SPP1 was found in the 73-year-old sample. Additionally, in-depth single-cell RNA-sequencing analysis identified associations between SPP1 and ITGAV, ITGB1, CD44, MMP3, and FN1. Notably, co-expression analysis highlighted a strong correlation between SPP1 and ITGB1. In summary, this study pioneers the identification of SPP1 as a gene implicated in ovarian aging. Further research into the role of SPP1 has the potential to advance precision medicine and improve treatment strategies for ovarian aging-related conditions.

8 July 2020 in Taiwanese Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
Li-Chuan HsuLi-Chuan Hsu
Li-Chuan Hsu
ACAn-Jen Chiang
An-Jen Chiang

1 June 2016 in Taiwanese Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
Li-Chuan HsuLi-Chuan Hsu
Li-Chuan Hsu
JLJung-Chia Lin
Jung-Chia Lin
SHSzu-Pei Ho
Szu-Pei Ho

Verified
Journal Article
Open access
PDF file
Li-Chuan HsuLi-Chuan Hsu
Li-Chuan Hsu
TTTing-Yu Tu
Ting-Yu Tu
HCHui-Yuan Chen
Hui-Yuan Chen
RCRenin Chang
Renin Chang
HYHei-Tung Yip
Hei-Tung Yip
JSJim Sheu
Jim Sheu
Background: This is an investigation of the human papillomavirus (HPV) infection and its correlation with the risk of ectopic pregnancy (EP). Methods: The cohort study includes 11,239 patients with newly diagnosed HPV infections between 2000 and 2012, and by using computer-generated random numbers, patients who do not have HPV infections are selected randomly as the comparison cohort. The HPV infection cohort is matched to comparison individuals at a 1:10 ratio by age and index year. All individuals included in the study were followed up to the point they developed EP, pulled-out from the insurance program, lost to follow-up, or until the end of 2013. A Cox proportional-hazards regression analysis was used to analyze the risk of EP with the hazard ratios (HRs) and 95% confidence intervals (CIs) between the HPV and control cohort. Results: The adjusted hazard ratio (aHR) of EP for HPV patients relative to controls is 1.70 (95% CI = 1.04, 2.78), indicating a positive correlation between EP and HPV in the 13-year follow-up period, after adjusting for age and relevant comorbidities. The sensitivity analyses yield similar results. Conclusions: A history of HPV infection is a potential risk factor associated with the development of subsequent EP in Taiwanese individuals, especially those diagnosed with an HPV infection within 3 years.

21 April 2022 in New England Journal of Medicine
Verified
Journal Article
Closed access
PKPei-Heng Kao
Pei-Heng Kao
Li-Chuan HsuLi-Chuan Hsu
Li-Chuan Hsu
To the Editor: In their article on the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial, Pitt et al. (Dec. 9 issue)1 report that patients who were treated with finerenone had a lower incidence of hospitalization for heart failure (one of the components of the primary composite outcome) than those who received placebo. However, additional issues should be considered. First, the data that were provided regarding baseline medications did not include the number and percentage of patients who were taking beta-blockers, which are used as therapy for heart failure and also may lower the risk . . .